Monday, 25 November 2013

INVOKANA™ (canagliflozin) Approved in the European Union for Treatment of Adults with Type 2 Diabetes 

Janssen-Cilag International NV (Janssen) announced today that the European Commission (EC) has approved INVOKANA™ (canagliflozin) in the European Union for the treatment of adults with type 2 diabetes mellitus, to improve glycaemic control[1]. Canagliflozin is an oral, once-daily medication, which belongs to a new class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors (BioSpace)

No comments:

Post a Comment